

Freedom of Information Request

Ref: UHB 19-763

21 January 2020

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

1. How many melanoma patients currently undergoing treatment are BRAF+ ?
The Trust is unable to identify which patients are BRAF+ve from the electronic systems used within the Bristol Haematology and Oncology Centre. To identify those patients the Trust will need to go through manually the notes of each patient. This would take the Trust more than 18 hours to complete and is therefore exempt from disclosure under Section 12 of the Freedom of Information Act.
2. In the past 3 months, how many melanoma patients were treated with the following:
Bevacizumab - 0
Cobimetinib - 0
Dabrafenib - 2
Dabrafenib AND trametinib - 19
Dacarbazine - 1
Encorafenib AND binimetinib - 4
Ipilimumab - 0
Ipilimumab AND Nivolumab - 6
Nivolumab - 20
Pembrolizumab - 31
Trametinib - 0
Vemurafenib - 1
Vemurafenib AND Cobimetinib - 0
Other active systemic anti-cancer therapy - 1
Palliative care – The Trust does not hold this information.
3. In the past 3 months how many patients were seen who had stage III resectable melanoma – These patients are seen by the Oncology/surgical teams in North Bristol Trust. Please contact North Bristol NHS Trust for data regarding this.
Of all stage III patients seen, how many received a complete resection ?
Of all stage III patients seen, how many were stage III a ?

These patients are seen by the Oncology/surgical teams in North Bristol Trust. Please contact North Bristol NHS Trust for data regarding this.

4. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for Non-small cell lung cancer (NSCLC)

Afatinib - 5

Alectinib - 5

Atezolizumab + bevacizumab + carboplatin + paclitaxel - 1

Atezolizumab mono - 7

Bevacizumab - 0

Brigatinib - 1

Ceritinib - 0

Crizotinib - 1

Dacomitinib - 0

Docetaxel monotherapy - 0

Durvalumab - 3

Erlotinib - 5

Gefitinib - 0

Gemcitabine – 15 (NB. Includes patient treated with Gemcitabine in combination)

Necitumumab – 0

Nintedanib with docetaxel - 2

Nivolumab - 4

Osimertinib - 5

Paclitaxel - 0

Pembrolizumab chemo in combination - 15

Pembrolizumab monotherapy - 67

Pemetrexed - 10

Pemetrexed with carboplatin - 10

Pemetrexed with cisplatin - 0

Ramucirumab - 0

Vinorelbine and cisplatin / carboplatin - 15

Other active systemic anti-cancer therapy - 10

Palliative care – The Trust does not hold this information.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol NHS Foundation Trust
Trust Headquarters

Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

FOI Team
UH Bristol NHS Foundation Trust